| Similar Articles |
|---|
 |
The Motley Fool
June 1, 2009
Brian Orelli |
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?   |
The Motley Fool
October 25, 2007
Brian Lawler |
Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation? |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
August 1, 2008
Brian Lawler |
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. |
The Motley Fool
August 7, 2009
Brian Orelli |
A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court. |
The Motley Fool
February 9, 2011
Brian Orelli |
Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years. |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
The Motley Fool
July 2, 2009
Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
The Motley Fool
October 22, 2009
Brian Orelli |
Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated. |
The Motley Fool
February 10, 2009
Brian Orelli |
Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma. |
The Motley Fool
March 15, 2007
Anders Bylund |
Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades. |
The Motley Fool
December 28, 2010
Brian Orelli |
No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005. |
The Motley Fool
April 23, 2009
Brian Orelli |
Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them. |
The Motley Fool
May 26, 2011
Brian Orelli |
Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis. |
The Motley Fool
October 24, 2008
Brian Orelli |
Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction. |
The Motley Fool
December 19, 2011
Brian Orelli |
Elan Turns It Around in 2011 Let's hope next year is as productive. |
The Motley Fool
May 9, 2011
Brian Orelli |
In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
April 25, 2007
Brian Lawler |
Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note. |
The Motley Fool
March 31, 2005
Stephen D. Simpson |
Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
February 22, 2007
Brian Lawler |
Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note. |
The Motley Fool
September 30, 2009
Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool
July 30, 2007
Brian Lawler |
The Good and Bad of Elan Investors, any bet on Elan is primarily a bet on the outcomes of Tysabri and AAB-001. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
June 18, 2007
Billy Fisher |
Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high. |
The Motley Fool
February 27, 2009
Brian Orelli |
Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already. |
The Motley Fool
January 20, 2010
Brian Orelli |
Those Are Fighting Words Alcon's minority shareholders fight back. |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
October 5, 2006
Brian Lawler |
Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up. |
The Motley Fool
January 25, 2010
Brian Orelli |
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. |
The Motley Fool
January 2, 2012
Anders Bylund |
What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012. |
The Motley Fool
October 26, 2009
Brian Orelli |
For Tysabri, 23 Is 10 Too Many The side effect rate is important. |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool
April 5, 2005
Charly Travers |
Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars. |
The Motley Fool
April 7, 2011
Brian Orelli |
When Zombies Attack, Investors Win Novartis is hoping that Prexige has as much success coming back from the dead as Tysabri has. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
April 8, 2008
Brian Lawler |
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history. |
The Motley Fool
February 28, 2008
Brian Lawler |
A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri. |
